Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Nanosonics Ltd (NAN) was established in 2001 and is best known for its trophon® technology. The trophon device was launched in 2009 and pioneered a new standard for the disinfection of ultrasound probes. The technology is utilised to disinfect intracavity and surface ultrasound probes with the aim of significantly reducing the occurrence of cross contamination between patients.
Nanosonics listed on the ASX in 2007 and by 2015, its market capitalisation had grown so significantly it joined the ASX 300 Index. In just one more year, the continuing rise of the Nanosonics share price would see the company form part of the ASX 200 Index.
Headquartered in Sydney, Nanosonics employs over 200 people and has offices in the United States, Canada, the United Kingdom and Europe.
In 2018, the company launched trophon® 2, the latest innovation in its ultrasound disinfection technology. Nanasonics also manufactures and distributes a range of consumables and accessories that are used as part of the trophon system.
The company is committed to ongoing research and the continuing development of superior disinfection technologies.
|23 Jul 2021||$5.35||$0.08||1.52%||419,166||$5.27||$5.40||$5.27|
|22 Jul 2021||$5.27||$0.05||0.96%||577,051||$5.27||$5.30||$5.21|
|21 Jul 2021||$5.22||$-0.01||-0.19%||555,577||$5.27||$5.33||$5.19|
|20 Jul 2021||$5.23||$-0.03||-0.57%||577,913||$5.25||$5.29||$5.21|
|19 Jul 2021||$5.26||$-0.07||-1.31%||309,118||$5.27||$5.34||$5.24|
|16 Jul 2021||$5.33||$0.00||0.00%||386,898||$5.33||$5.40||$5.30|
|15 Jul 2021||$5.33||$-0.18||-3.27%||978,835||$5.48||$5.50||$5.31|
|14 Jul 2021||$5.51||$0.09||1.66%||771,546||$5.44||$5.54||$5.42|
|13 Jul 2021||$5.42||$0.18||3.44%||952,291||$5.25||$5.48||$5.25|
|12 Jul 2021||$5.24||$0.10||1.95%||513,503||$5.15||$5.25||$5.12|
|09 Jul 2021||$5.14||$-0.11||-2.10%||855,408||$5.21||$5.22||$5.07|
|08 Jul 2021||$5.25||$0.13||2.54%||1,173,138||$5.14||$5.27||$5.07|
|07 Jul 2021||$5.12||$-0.26||-4.83%||1,965,008||$5.19||$5.19||$4.99|
|06 Jul 2021||$5.38||$-0.23||-4.10%||578,617||$5.65||$5.65||$5.37|
|05 Jul 2021||$5.61||$-0.03||-0.53%||486,457||$5.64||$5.71||$5.58|
|02 Jul 2021||$5.64||$-0.15||-2.59%||960,074||$5.82||$5.94||$5.63|
|01 Jul 2021||$5.79||$-0.08||-1.36%||426,397||$5.85||$5.89||$5.78|
|30 Jun 2021||$5.87||$-0.02||-0.34%||705,305||$5.97||$6.08||$5.86|
|29 Jun 2021||$5.89||$0.05||0.86%||841,330||$5.85||$5.91||$5.72|
|28 Jun 2021||$5.84||$-0.13||-2.18%||926,742||$6.00||$6.02||$5.78|
|25 Jun 2021||$5.97||$0.14||2.40%||751,535||$5.90||$6.02||$5.85|
|28 May 2021||Michael Kavanagh||Exercise||342||$1,905,606||
Conversion of securities. 405,104 - Performance Rights & Share Appreciation Rights
|28 May 2021||Michael Kavanagh||Buy||342||$1,905,606||
Conversion of securities.
|18 Mar 2021||Michael Kavanagh||Issued||352||$2,130,701||
Issue of securities. 747,839 - Share Appreciation Rights & Performance Rights
|25 Feb 2021||Lisa McIntyre||Buy||8||$49,980||
|27 Jan 2021||Michael Kavanagh||Issued||19||$135,695||
Issue of securities. 395,657 - Performance Rights
|14 Oct 2020||Geoff Wilson||Buy||4||$25,238||
|02 Sep 2020||Geoff Wilson||Buy||4||$25,024||
|02 Sep 2020||Lisa McIntyre||Buy||8||$49,930||
|31 Aug 2020||Steven Sargent||Buy||16||$99,548||
|Mr Maurie Stang||Non-Executive ChairmanNon-Executive Director||Nov 2000||
Mr Stang has more than two decades of experience building and managing companies in the healthcare and biotechnology industry in Australia and internationally. His business development and marketing skills have resulted in the commercialisation of intellectual property across global markets. He is a Non-executive Director of Vectus Biosystems. He is also a member of Risk, People and R&&D and Innovation Committee.
|Dr Lisa Margaret McIntyre||Non-Executive Director||Dec 2019||
Dr McIntyre has executive background in strategy, particularly in the areas of medical technology and healthcare, and acted as a partner at L.E.K. Consulting in the US and Australia where she led the Asia Pacific Health practice. Dr McIntyre was a Director of the Garvan Institute of Medical Research for 12 years and on the advisory committee of the NSW Generations Fund. She is currently a Non-executive Director of HCF Group, Insurance for NSW (icare) and Studiosity Pty Ltd. Dr McIntyre is also a member of Risk and R&D Innovation Committee.
|Mr David Fisher||Non-Executive Director||Jul 2001||
Dr Fisher is a founding partner of Brandon Capital Partners, a Australian venture capital provider. He has more than 35 years operating experience in the biotechnology and healthcare industry in Australia and overseas. He held senior positions with Pharmacia AB (now part of Pfizer, Inc) and was CEO of Peptech Limited (now part of Cephalon Inc.). He is also a Chairman of the R&D Innovation Committee and member of Risk Committee.
|Mr Michael Kavanagh||Chief Executive OfficerManaging Director||Jul 2012||
Mr Kavanagh has more than 26 years of international commercial experience in the healthcare market, having held local, regional and global roles in medical device and pharmaceutical industries. Before joining Nanosonics, he was Senior Vice President of Global Marketing for the medical device company Cochlear Ltd, a position he held for more than 10 years. He is also a member of R&D Innovation Committee.
|Ms Marie Elizabeth McDonald||Non-Executive Director||Oct 2016||
Ms McDonald has background in corporate and commercial law, having practised for many years as a partner at Ashurst. She was Chair of the Corporations Committee of the Business Law Section of the Law Council of Australia (2012 to 2013) and was a member of the Australian Takeovers Panel from 2001 to 2010. Ms McDonald is currently a Non-executive Director of CSL Limited, Nufarm Limited and the Walter and Eliza Hall Institute of Medical Research. She is also a member of Risk and People Committee.
|Mr Steven Andrew Sargent||Non-Executive Deputy ChairmanNon-Executive Director||Jul 2016||
Mr Sargent had a 22-year career with General Electric and has global experience across a range of industries, including financial services and healthcare. He was Vice President and Officer of GE, a member of GE's Corporate Executive Council and CEO of GE Australia NZ. Mr Sargent is currently a Director of Origin Energy, Chairman of OFX Group, a Director of the Great Barrier Reef Foundation and Chairman of The Origin Foundation. Previously, Mr Sargent was a Director of Veda Group, a Director of Bond University and a Director of the Business Council of Australia. He is also a member of Risk, R&D Innovation Committee and Chairman of People Committee.
|Mr Geoff Raymond Wilson||Non-Executive Director||Jul 2019||
Mr Wilson has a breadth of local and international executive leadership and director experience together spanning more than 37 years, including many years with KPMG in Australia, Hong Kong and the USA. He has a background in finance, audit and risk management, as well as in Asia Pacific markets. Mr Wilson is currently a Director of TOLL Holdings Limited, HSBC Bank Australia Limited, Future Generation Global Investment Company Limited, ipSCAPE, and Sydney Symphony Limited. He is also an Ambassador for the Australian Indigenous Education Foundation. He is also a Chairman of Risk Committee and member of People Committee.
|Mr McGregor Grant||Chief Financial OfficerCompany Secretary||
|McGregor Grant||Chief Financial OfficerCompany Secretary||
|HSBC Custody Nominees (Australia) Limited||88,659,425||29.49%|
|J P Morgan Nominees Australia Pty Limited||43,213,979||14.37%|
|Citicorp Nominees Pty Limited||15,863,058||5.28%|
|UBS Nominees Pty Ltd||13,203,244||4.39%|
|Mr Bernard Stang||8,692,111||2.89%|
|National Nominees Limited||8,632,927||2.87%|
|Mr Maurie Stang||8,629,534||2.87%|
|Mr Steve Kritzler||8,489,737||2.82%|
|BNP Paribas Noms Pty Ltd <Drp>||7,296,447||2.43%|
|BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C>||5,850,456||1.95%|
|Asia Union Investments Pty Limited||2,500,000||0.83%|
|Dr Harry Hirschowitz||2,139,090||0.71%|
|Avanteos Investments Limited <2349414 Hofbauer A/C>||1,200,000||0.40%|
|Mr Michael Kavanagh||1,018,363||0.34%|
|HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C>||925,122||0.31%|
|Powerwrap Limited <Scheme - Iml Trades A/C>||903,206||0.30%|
|AMP Life Limited||800,775||0.27%|
|Larinda Pty Ltd <Bg Superannuation Fund A/C>||800,000||0.27%|
|Australian Foundation Investment Company Limited||780,000||0.26%|
|Citicorp Nominees Pty Limited <Colonial First State Inv A/C>||681,938||0.23%|